Chronic heart failure (CHF) is increasingly common worldwide with an estimated prevalence of 2% in people between 50 and 60 years of age, 1 and up to 10% in people over 70. 2 The cardinal symptom of CHF is exercise intolerance, usually due to breathlessness and fatigue. Physical signs in CHF are uncommon (particularly in treated patients) and non-specific. Patients presenting with exercise intolerance, most frequently initially to their general practitioner, therefore pose a diagnostic problem, a clinical diagnosis of CHF being difficult to make accurately. However, certain groups are at higher risk of CHF, allowing the clinician to select patients who should be further investigated. The aim of this article is to assess the frequency of CHF in people with obesity, hypertension and T2DM, and to discuss how each co-morbid condition might predispose to, and complicate, the clinical diagnosis of CHF.
control populations, with 7.7% vs. 3.4% developing the condition over 30 months on a background prevalence of CHF of 11.8% at baseline, compared with 4.5% in the controls. 14 Insulin resistance, independent of hyperglycaemia, predisposes to CHF, 15, 16 and in patients without obvious heart failure is associated with echocardiographic markers of LV dysfunction. 17 In studies enrolling people with risk factors for cardiovascular disease, the admission rate for CHF is directly related to fasting blood glucose. 18 The reverse situation is also true: more patients with heart failure than expected also have diabetes mellitus. 19, 20 The situation is complicated by the fact that chronic heart failure is characterised by a general switch from anabolic to catabolic processes, 21 hence insulin resistance is a common finding in patients with CHF, even amongst those with normoglycaemia. 16, [22] [23] [24] Heart failure patients with diabetes have reduced functional capacity, 25 and poorer clinical outcomes, 21, 26 with a high mortality (figure 2) 4 compared with those with heart failure alone.
Recent data do not demonstrate sex-related differences in heart failure in diabetes (figure 1). 27 For example, in people without diabetes, far more men than women have heart failure. However, data at 20 years from the Framingham cohort suggest that in subjects with diabetes, there is no sex-related difference in the prevalence of CHF, suggesting that the relative impact of diabetes is greater in women than men. 10 Subclinical myocardial dysfunction is even more common than overt heart failure in diabetic patients. TDI, which can be used to estimate longitudinal LV function (shortening of the heart from apex to base), showed reduced LV strain, and impaired systolic and diastolic velocities in 27% of 120 T2DM subjects without overt heart failure, with 16% demonstrating systolic dysfunction alone and 10% both systolic and diastolic dysfunction. 28, 29 Longitudinal LV systolic and diastolic dysfunction as 'early' diabetic cardiomyopathy might therefore be extremely common. [30] [31] [32] [33] Compensatory increases in radial contractility (contraction along the short axis of the heart) preserves cardiac output in patients with diabetes in those with reduced longitudinal function. 34 Even if resting values of systolic function are normal, impaired contractility can often be brought out by exercise. 35 Diabetes and the metabolic syndrome are associated with increased LV mass. 36 LV hypertrophy is associated with an increased risk of heart failure, but in the presence of diabetes, the incidence increases to 2% per annum. 37 It is not clear from published data whether females are more or less likely to develop heart failure or early 'subclinical' ventricular dysfunction, but the direct relationship between glucose and increased wall thickness and ventricular mass is stronger in women than men. 16 
Coronary artery disease.
Diabetes is associated with a 2-4 fold increase in cardiovascular disease. 5, 6 The most frequent manifestation of the vascular complications of T2DM are the consequences of accelerated atherosclerosis and resultant ischaemic heart disease, with myocardial infarction the most obvious presentation. Patients with T2DM also have an increased incidence of cerebrovascular disease, renovascular disease and peripheral vascular disease. However, vascular abnormalities may predate evident atherosclerosis, 7 and may be present even prior to the diagnosis of T2DM. 8 CAD is the most frequent cause of LV systolic dysfunction generally, and is common in patients with diabetes. Individuals with diabetes are more likely than those without to have silent ischaemia (33% vs. 15%) and silent myocardial infarction (18% vs. 7%), 9 which may result in significant LV dysfunction without chest pain. Furthermore, even in those who do experience chest pain with ischaemia, chest pain occurs late during the ischaemic episode, such that in an obese individual with exercise intolerance, a low level of daily activity may lead to recurrent ischaemia but infrequent chest pain.
Diabetic cardiomyopathy
In addition to the frequent occurrence of CAD in diabetes, there may also be a 'diabetic cardiomyopathy', 38, 39 its aetiology independent of ischaemia. The term was first proposed by Danish endocrinologist Knud Lundbaek in 1954. 40 Diabetic cardiomyopathy might include a spectrum of dysfunction, as CHF now does, encompassing mild diastolic dysfunction with LV hypertrophy through to a true dilated cardiomyopathy with important systolic dysfunction. Alternatively, diabetic cardiomyopathy may manifest as cardiomyocyte adaptations which may increase the susceptibility of the myocardium to other risk factors such as hypertension or ischaemia.
The aetiology of such a cardiomyopathy remains unclear, but probably includes hyperglycaemia and insulin resistance, 41 with specific alterations in endothelial function, cardiac ultrastructure, microangiopathy and cardiomyocyte metabolism.
In the normal heart, carbohydrate is used to generate 20-40% of energy, and fatty acid metabolism 60-80%. However, insulin resistance leads to impaired glucose uptake and metabolism, such that cardiomyocyte energy production shifts from glucose to fatty acid utilisation. Increased serum and cellular concentrations of free fatty acids are a typical feature of T2DM, 42 and both exacerbate impaired glucose uptake, 43, 44 possibly by reducing the expression of the GLUT-4 glucose transporter. 40 Not only can intracellular free fatty acids be converted to ceramide and diacylglycerol, both of which contribute to oxidative stress and cardiomyocyte apoptosis, 45, 46 but they also inhibit glucose metabolism. In turn, this hyperglycaemia may also cause glycosylation of intracellular transcription factors, thereby modifying transcriptional activation and thus protein turnover. 47 The beta-oxidation of free fatty acids produces more ATP than glucose oxidation, but at significantly higher oxygen consumption. Patients with coronary artery disease might thereby become more susceptible to ischaemia. Moreover, glucose uptake and metabolism are thought to be important in the preconditioning effect and the protection of myocytes from ischaemia. 48 In animal models of diabetes there is impaired ATPase activity of the cardiac myofibrils actomyosin and myosin, 49, 50 due to altered myosin ATPase isoenzyme composition, and phosphorylation of regulatory proteins. 51, 52 Mitochondrial activity may also be impaired as a result of hyperglycaemia and oxidative stress, particularly in those mitochondria lying between myofibrils. 53 Elevated glucose and free fatty acid levels lead to upregulation of PKC, which has powerful pro-atherosclerotic effects. 54 In the myocardium, PKC inhibits the sodiumpotassium ATPase, 55 and targeted overexpression of PKCβ2 can induce cardiomyopathy in animal models. 56 Prolonged exposure of proteins to hyperglycaemia results in non-enzymatic reactions with glucose, leading to the formation of AGEs. 57 AGEs are able to form cross-links between collagen and other molecules, where normally these proteins would only be linked at C-and N-terminals. The increased cross-linking of collagen increases myocardial stiffness, 58, 59 resulting in impaired relaxation of the myocardium, or reduced LV compliance, and may manifest as reduced diastolic velocities on echocardiography and even diastolic dysfunction. The stiffness does seem to be reversible. 60 In addition, activation of RAGE increases the transcription of proinflammatory genes, 61 causing an inflammatory response in the myocardium.
Ultrastructural changes with persistent hyperglycaemia include increased collagen content, vacuolation, reduced cardiomyocyte size and myofibrillary degeneration, all possibly due to oxidative stress. 62 Reduced myocardial contractility in T2DM might also be due to reversible hyperglycaemia and insulin-induced reductions in sarcoplasmic reticulum calcium uptake. [63] [64] [65] Hyperglycaemia and insulin resistance are associated with reduced NO bioavailability and NO resistance, 66, 67 hence this may be another contributor to diastolic dysfunction in heart failure. 68 Finally, myocardial blood flow reserve is abnormal in individuals with diabetes without epicardial coronary disease, 69 and there is reduced myocardial capillary density. 70 Hypertension and renal dysfunction in type 2 diabetes mellitus Diabetic nephropathy, a common consequence of T2DM, leads to accelerated cardiovascular disease and hypertension. Patients with diabetes, hypertension and LV hypertrophy have a high incident rate of heart failure (1.9%). 71 Increased urinary albumin excretion rate is an independent risk factor for the development of CHF even in non-diabetic individuals, 37 but once there is established renal impairment in the presence of diabetes mellitus, the risk of heart failure rises to 5%, with the degree of renal dysfunction being more important than age or the presence of overt vascular disease. The influence of hypertension in the development of heart failure will be discussed further below.
Obesity
In patients with established CHF, being overweight is, in most (but not all) studies, associated with reduced mortality, [72] [73] [74] [75] [76] although hospitalisation rates are the same for obese and non-obese patients with CHF. 77 In non-CHF populations, however, obesity contributes to insulin resistance and is associated with hypertension, thereby being causally related to coronary disease. Obesity also has adverse influences on haemodynamics, with a hyperdynamic circulation, sympathetic activation, altered myocardial substrate metabolism and increased plasma volume.
Obesity, and specifically abdominal obesity, is an independent risk factor for heart failure, [78] [79] [80] [81] (figure 3 ) and the risk is the same for obese men and obese women. 82 A BMI of > 35 is associated with impaired LV systolic function and increased myocardial reflectivity, suggestive of increased collagen content. 83 In asymptomatic non-diabetic obese subjects up to 82% have LV hypertrophy, 43% LV dilatation, and 55% diastolic dysfunction. 84 Even in those with apparently normal global LV systolic function, TDI reveals impaired longitudinal function with lower systolic and diastolic velocities than in non-obese control subjects. 81 Other changes include echocardiographic changes suggestive of increased myocardial collagen content. 85 These changes together are suggestive of an 'obesity cardiomyopathy'. Furthermore, the evidence for a causal relationship between obesity and LV impairment is strengthened by the observation that in both men and women, weight reduction leads to reduced LV end-diastolic volume, improved LV inflow velocities, smaller left atrial diameter and reduced LV wall stress. 86, 87 Prevalence and incidence of heart failure in obesity. In more than 5,800 people, followed for 14 years, even those that were modestly overweight were at increased risk of developing heart failure, 77 with an attributable risk of heart failure due to obesity of 14% in women and 8.8% in men. The risk of incident CHF in adults with a BMI > 30 was 1% per year for men and 0.7% per year for women. Aetiology of the obesity cardiomyopathy. A number of factors are likely to contribute to the development of myocardial dysfunction and a comprehensive review of all of the potential agents is beyond the scope of this article. For example, in addition to the persistent sympathetic nervous system activation to which the myocytes of obese subjects are exposed, [88] [89] [90] [91] human adipocytes seem to be capable of secreting a cardioactive substance that is negatively inotropic, depressing shortening amplitude and intracellular peak calcium levels. 92 However, one of the agents about which most is known is leptin. Leptin is a hormone produced by adipocytes in response to feeding which suppresses appetite by acting on the appetite centre of the hypothalamus. Increased leptin levels are seen in obesity. Acute increases in leptin levels protect the heart and other tissues from ectopic lipid deposition by limiting dietary intake, upregulation of fatty acid oxidation and downregulation of lipogenesis in peripheral tissues. 93 The effects of longer-term increased levels of leptin on cardiomyocytes include structural and metabolic changes. In cultured myocytes, leptin exposure has a mitogenic effect, 94 and also leads to myocyte elongation, 95 and hypertrophy. 96 Leptin causes an acute increase in cardiomyocyte fatty acid oxidation. Long-term exposure to elevated leptin levels stimulates increased fatty acid uptake. Hence, although leptin leads acutely to a drop in cardiomyocyte fatty acid content, in the long term there is an overall decrease in fatty acid oxidation and increased cellular uptake, leading to cardiomyocyte fatty acid loading. 97 Increased levels of intracellular free fatty acids can initiate the pathways of programmed cell death, termed lipoapoptosis. 98 Sleep apnoea, obesity and heart failure. Sleep apnoea may be present in up to half of patients with CHF, depending upon the population studied. 99 The combination of OSA and obesity leads to an increase in left atrial size, impaired LV diastolic function, and impaired markers of right ventricular function. 100 Patients with daytime sleepiness and OSA frequently have underlying ventricular dysfunction with a low cardiac index. 101 Self-reported sleep disturbance is associated with an increased incidence of heart failure in obese middle-aged men. 102 Although OSA is associated positively with the metabolic syndrome and serum leptin and adiponectin levels, this is not independent of its relationship with obesity, suggesting that these relationships are driven by the connection between obesity and OSA. 103 
Men

Hypertension
Hypertension has long been recognised as an independent risk factor for the development of heart failure, 104, 105 with LV hypertrophy as a particularly ominous sign predicting morbidity and heart failure death. 106 However, once a diagnosis of heart failure has been made, high blood pressure is associated with improved survival. The reasons for this may be that the ability to maintain a high blood pressure implies greater cardiac reserve, and because patients with hypertension are more likely to tolerate treatments such as ACE inhibitors and beta-blockers. Prevalence and incidence of heart failure in hypertension. In Western populations, between 6 and 10% of cases of heart failure are thought to be due to hypertension, 107,108 with significant ethnic variations. 109 Hypertension increases the risk of heart failure twofold in men and threefold in women over that seen in normotensive subjects. 110 Hypertension in men is more likely than in women to cause systolic heart failure. 106 Impairment of longitudinal systolic function is present in up to 34% of patients with hypertension and otherwise normal LV function. 111 Aetiology of 'hypertensive' heart failure. Longstanding hypertension leads to LV hypertrophy. It remains a subject of much research at which point, and why, pressure-loaded ventricles eventually dilate and ventricular systolic dysfunction ensues. Some hearts are prone to early dilatation or heart failure rather than hypertrophy, and this is likely to be due to differential gene expression. 112 Additional influences include abnormalities of endothelial function; for example, deficiencies of NO can lead to structural remodelling of cardiac capillary network manifested as angiogenesis and angiopathy. The predominance of angiopathy in this setting may accelerate the loss of capillary endothelium and subsequently myocardial dysfunction. 113 A consistent finding in patients soon after the diagnosis of hypertension is myocardial interstitial fibrosis with increased type 1 collagen deposition and myocyte hypertrophy. 114 Later, there is increased cardiomyocyte apoptosis. 115, 116 
Diagnostic difficulties
Even in patients with normal body habitus, CHF can be difficult to diagnose from the history and physical examination without further investigations. 117 Complicating the diagnosis of heart failure in obese patients with diabetes is the fact that the cardinal symptom of heart failure -exercise intolerance -is commonly seen in the obese. Simple investigations are, however, helpful. A normal ECG is strongly predictive of normal LV function, 118 although the sensitivity of an ECG for the early deterioration in longitudinal function is unproven. Ultimately, some form of cardiac imaging is necessary to establish the diagnosis of heart failure, and this is usually an echocardiogram. In obese subjects with diabetes, there is inevitably reduced quality of echocardiographic images, and additional imaging, particularly with cardiac magnetic resonance imaging (although large abdominal girth may limit access for very obese subjects) or cardiac single photon emission computed tomography may be needed.
N-terminal BNP is increasingly used in the diagnosis of heart failure. BNP levels are generally lower despite higher LV end-diastolic pressures in the obese and people with metabolic syndrome, whether they have CHF or not. [119] [120] [121] [122] [123] However, if this is taken into account, BNP retains similar diagnostic significance in obese subjects as in non-obese subjects. 124 Exercise capacity is not a good guide to the origin of breathlessness, as morbid obesity and chronic heart failure are both associated with a similar reduction in exercise capacity, and decreasing exercise capacity is related just as strongly to an adverse prognosis in both groups. 125 
Discussion
Diabetes mellitus is a major risk factor for the development of LV dysfunction even in the absence of symptoms of coronary disease: 25% of asymptomatic subjects with T2DM have evidence of systolic ventricular dysfunction. Independent of the major influences of hypertension and diabetes or impaired glucose tolerance, obesity is also an important factor for the development of heart failure, with up to 35% of obese patients having some degree of ventricular dysfunction. Hypertension is perhaps the longest-recognised risk factor for the development of heart failure, with up to 34% of patients with a history of hypertension demonstrating some degree of LV dysfunction. However, there are no data examining the prevalence of LV dysfunction in patients with all three of these major risk factors.
Each risk factor is modified by the sex of the patient. Women are less likely than men to develop coronary artery disease and systolic heart failure, and are more likely to have symptoms consistent with heart failure in the presence of normal systolic function. However, the attributable risk in women from a combination of diabetes, hypertension and obesity is greater than for men, since their baseline risk is lower. Female sex would seem to offer much less protection from heart failure in the presence of these risk factors than from ischaemic heart disease.
Although careful physical assessment with appropriate investigations can identify those at most risk, a screening programme has been proposed in such patients. Introducing screening programmes can be fraught, particularly because the value of those in daily practice, such as for cervical and breast cancer, are still debated. 126 However, we believe that two considerations make screening to detect LV dysfunction in at-risk individuals with diabetes something that should be considered. Firstly, the prevalence of LV systolic dysfunction is high enough, the screening methodology (echocardiography) is benign enough, and the potential preventative therapy (with ACE inhibitors and beta blockers) is sufficiently well established that there is a high likelihood of benefit and very low likelihood of harm coming from screening; and secondly, the diabetic population is one already well-versed in screening for complications. Addition of regular surveillance echocardiography should, we think, be studied with some urgency.
Conclusion
The prevalence of LV systolic dysfunction in obese patients with diabetes and hypertension but no overt coronary artery disease may be of the order of 30%, with women at slightly lower risk than men. With such a high prevalence, and the availability of successful treatments, it may be time to consider screening initiatives to identify LV systolic dysfunction in diabetic patients, in order to prevent the progression to overt heart failure. 
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